Posted on May 23rd, 2019 in
News
Dundee, UK, 23rd May 2019: Ubiquigent Limited, a company focused on enabling and supporting ubiquitin system-focused drug discovery, announced today that it had entered into an agreement with Dorian Therapeutics to provide access to one of its novel small molecule…
Read More »
Posted on August 22nd, 2018 in
News
Dundee, UK – 22nd August 2018: Ubiquigent Limited, a company specialising in providing ubiquitin cell-signalling system drug discovery services, research tools and novel targeted chemistry, announced today that it has launched REDOXprofiler™. The new service, validated following a collaboration with…
Read More »
Posted on August 15th, 2018 in
News
Dundee, UK, 15th August 2018: Ubiquigent Limited, a company focused on enabling and supporting ubiquitin system targeted drug discovery, announced today that it was awarded a new grant from Innovate UK as part of its Investor Accelerator Pilot to support…
Read More »
Posted on April 5th, 2018 in
News
Dundee, UK, 5th April 2018: Ubiquigent Limited announced today that it has entered into a multi-year strategic R&D collaboration agreement with FORMA Therapeutics for the design and development of novel deubiquitylase (DUB) enzyme inhibitors. Under the terms of the collaboration…
Read More »
Posted on January 16th, 2018 in
News
Posted on January 19th, 2017 in
News
Ubiquigent awarded Innovate UK grant to develop novel compound libraries targeting deubiquitylase (DUB) enzymes Dundee, UK, 19th January 2017: Ubiquigent Limited, a company specialising in providing ubiquitin cell-signalling system drug discovery services and research tools, announced today that it has…
Read More »
Posted on September 14th, 2016 in
News
Ubiquigent launches the first novel compound library designed to target Deubiquitylase (DUB) enzymes - DUBtarget™-001 Dundee, UK, 14th September, 2016: Ubiquigent Limited, a company specialising in providing ubiquitin cell-signalling system drug discovery services and research tools, announced today that it…
Read More »
Posted on May 26th, 2016 in
News
Horizon's X-MAN® cell lines to be made available in conjunction with Ubiquigent's ubiquitin-related Drug Discovery Services Cambridge, UK, 26 May 2016: Horizon Discovery Group plc (LSE: HZD) ("Horizon"), the world leader in the application of gene editing technologies including…
Read More »
Posted on May 12th, 2016 in
News
Take a look at a great article that was published today in Nature describing how the Division of Signal Transduction Therapy (DSTT) enables pre-competitive access to ubiquitin system research at the University of Dundee. Our friends at the University of…
Read More »
Posted on February 24th, 2016 in
News
Dundee, UK, 24th February, 2016: Ubiquigent Limited, a company specialising in providing ubiquitin cell-signalling system drug discovery services and research tools, announced today that it has significantly enhanced its drug discovery service capabilities by strengthening its commercial and chemistry teams…
Read More »
